Polycations on the
Classical and Alternative Pathways of
Complement. Immunopharmacology, 17(2), 65-72
(1989).
6. Martindale The Extra Pharmacopoeia, 30th ed.,
Reynolds, J.E.F., ed., The Pharmaceutical
matrix
and adhesion proteins, Oxford Univ. Press, (1993).
64. Vilim V. and Fosgang A.J., Biochem. J., 304, 887-894,
(1994).
65. Vilim V. and Fosgang A.J., Biochem. J., 293, 165-172,
(1993).
66. Flannery C.
matrix
and adhesion proteins, Oxford Univ. Press, (1993).
64. Vilim V. and Fosgang A.J., Biochem. J., 304, 887-894,
(1994).
65. Vilim V. and Fosgang A.J., Biochem. J., 293, 165-172,
(1993).
66. Flannery C.
effects of clarithromycin in comparison with
gentamicin and placebo in volunteers. Drug Saf.,
7(4), 304-9 (1992).
3. Dehne, M.G. et al., Tamm-Horsfall protein, alpha-1-
and beta-2-microglobulin as
S., and Ross, R., Progr. Cardiovasc.
Dis., 26, 355 (1984).
22. Waterfield, M., et al., Nature, 304, 35 (1983).
23. Robbins, K., et al., EMBO J., 4, 1783 (1985).
24. Johnsson, A., et al.
S.M., and Ross, R., Progr. Cardiovasc.
Dis., 26, 355 (1984).
23. Waterfield, M. et al., Nature, 304, 35 (1983).
24. Robbins, K.C. et al., EMBO J., 4, 1783 (1985).
25. Johnsson, A. et al., Proc. Natl
., and Ross, R., Progr. Cardiovasc. Dis.,
26, 355 (1984).
23. Waterfield, M., et al., Nature, 304, 35 (1983).
24. Robbins, K., et al., EMBO J., 4, 1783 (1985).
25.
S.M., and Ross, R., Prog. Cardiovasc.
Dis., 26, 355 (1984).
23. Waterfield, M.D. et al., Nature, 304, 35 (1983).
24. Robbins, K. et al., EMBO J., 4, 1783 (1985).
25. Johnsson, A. et al., Proc. Natl. Acad
., and Ross, R., Progr. Cardiovasc.
Dis., 26, 355 (1984).
23. Waterfield, M., et al., Nature, 304, 35 (1983).
24. Robbins, K., et al., EMBO J., 4, 1783 (1985).
25. Johnsson, A., et al., Proc. Natl
., and Ross, R., Prog. Cardiovasc.
Dis., 26, 355 (1984).
23. Waterfield, M.D., et al., Nature, 304, 35 (1983).
24. Robbins, K., et al., EMBO J., 4, 1783 (1985).
25. Johnsson, A., et al., Proc. Natl.
S., and Ross, R., Progr. Cardiovasc.
Dis., 26, 355 (1984).
23. Waterfield, M., et al., Nature, 304, 35 (1983).
24. Robbins, K., et al., EMBO J., 4, 1783 (1985).
25. Johnsson, A., et al., Proc. Natl.
S., and Ross, R., Progr. Cardiovasc.
Dis., 26, 355 (1984).
23. Waterfield, M., et al., Nature, 304, 35 (1983).
24. Robbins, K., et al., EMBO J., 4, 1783 (1985).
25. Johnsson, A., et al., Proc. Natl.
3 (5), 289-293 (2001).
6. Heimann, R. et al., Separating favorable from
unfavorable prognostic markers in breast cancer:
the role of E-cadherin. Cancer Res., 60, 298–304
(2000).
7. Hunt, N.C.A.
J. et al., J. Cell Biol., 87, 386-397 (1980).
36. Carafoli, E. et al., Ann. N.Y. Acad. Sci., 402, 304-
328 (1982).
37. Caroni, P. and Carafoli, E., J. Biol. Chem., 256,
3263-3270(1981).
38. Newsholme
28. Tracey, K.J., et al., Nature, 330, 662 (1987).
29. Pujol-Borrell, R., et al., Nature, 326, 304 (1987).
30. Waage, A., et al., Lancet, 1, 355 (1987).
31. Tsukada, N., et al., J. Neurol. Sci.
peritoneum
predicts effectiveness of agents in vivo.
Proc.Am.Assoc.Cancer Res. 1996; 37 Abstract
2066: 304-304. (Abstract)
56. Redman CA, Kusel JR: Distribution and
biophysical properties of fluorescent